A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers.

2014-08-27 03:40:39 | BioPortfolio


This study is to assesss the safety and immunogenicity of vaccine based on Modified Vaccinia Ankara (MVA) expressing the 85A antigen (from Mycobacterium. tuberculosis). This vaccine is delivered intrdermally by a needle injection in healthy volunteers.


1. This is a phase I study to assesss the safety and immunogenicity a recombinant MVA encoding a secreted antigen from Mycobacterium. tuberculosis Antigen 85A, delivered intrdermally by a needle injection in healthy BCG naive volunteers.

2. Selection of volunteers

Volunteers for the study will be recruited through advertisements. Each volunteer will have received an information sheet concerning the study and will have agreed to participate in writing. Volunteers will be given at least 48 hours between reading the information leaflet and agreeing to participate. Female volunteers will be told of the theoretical risk of congenital anomaly should they become pregnant during the study and only those who undertake to take precautions to avoid pregnancy during the study period will be eligible. Volunteers will give signed consent for their GP’s to be notified about their participation in the trial. The GP will be faxed a letter on the day of screening and asked to reply if they know of a reason why the volunteer should not take part. The signed consent form will also be faxed with the letter.

3. Screening

Volunteers will be asked to sign the informed consent form for screening. The following will be performed:

- Medical history and examination

- Laboratory evaluations – including clinical chemistry, haematology, HLA typing, anti-vaccinia antibodies, anti-HBV antibodies, anti-HCV antibodies, anti-HIV antibodies

- Heaf test – to exclude prior exposure to TB

- Urinalysis and urine pregnancy test if female

4. Inclusion Criteria

- Healthy adult aged 18-45 years.

- Normal medical history and physical examination.

- Normal urine dipstick, blood count, liver enzymes, and creatinine.

5. Exclusion Criteria

1. Exposure to TB/BCG vaccination at any point. Previous residence in a TB endemic area.

2. Clinically significant history of skin disorder (eczema, psoriasis, etc.), allergy, immunodeficiency, cardiovascular disease, respiratory disease, endocrine disorder, liver disease, renal disease, gastrointestinal disease, neurological illness, psychiatric disorder, drug or alcohol abuse.

3. Oral or systemic steroid medication or the use of immunosuppressive agents.

4. Positive HIV antibody test, HCV antibody test or positive HBV serology except post-vaccination.

5. Positive Heaf test

6. Confirmed pregnancy

7. Previous MVA immunisations

6. Withdrawal Criteria

1. Withdrawal of consent by subject for any reason

2. Loss to follow-up

3. Non-compliance with study procedures

4. Protocol violation

5. Serious adverse event (as defined in Appendix 3)

6. Any other reason at discretion of the Principal Investigator

7. Confirmed pregnancy during study period

7 Immunisation

On Day 0 and Day 21, subjects will receive a single intradermal injection of 5 x 107pfu in 0.1ml over the deltoid muscle. Subjects will be observed for an hour after all immunisations. Vital signs will be monitored at 30 and 60 minutes post-immunisation. Local reactions at the site of administration will be evaluated at 60 minutes.

A photograph of the injection site may be taken at 48 hours (with written consent). The injection site will be reviewed 7 days after each immunization.

Blood will be taken at the following time points: At the screening visit*, prior to the first vaccination, *1 week after the first vaccination, prior to the second vaccination, *1 week after the second vaccination, 4 weeks, 8 weeks, *12 weeks and 24 weeks after the second vaccination. Up to 55 mls will be taken at any one time with the total being no more than 500 mls over the study period. *Samples taken on these dates will be tested for full blood count and biochemical screen. Immunological assays will be performed at all time points to determine vaccine immunogenicity. A pregnancy test will be performed on screening and each vaccination day prior to vaccination for female volunteers. Peripheral blood mononuclear cells will be prepared for cellular immunological assays to be performed without or following cryopreservation. Other serological measures of immune response, i.e. antibody titres, will be assayed on frozen plasma samples.

At the end of the six month follow-up period, volunteers will be offered BCG immunisation. If they accept, imunological monitering will continue for a further six months. 50mls of blood will be taken for cellular immunological assays 1 week, 2 weeks, 1 month, 2 months, 3 months and 6 months after BCG immunisation.

All blood tests will be taken within 1-3 days of the due date as described in the schedule above.

8 Endpoints

The occurance and severity of local side-effects. The occurance and severity of systemic side-effects. The induction of T cell responses (as measured by an interferon-gamma Elispot assay).

Proliferation assays and cytotoxic T cell assays will be performed on strong CD4+ and CD8+ responses respectively.

This study has been completed.

Study Design

Allocation: Non-Randomized, Control: Uncontrolled, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention




MVA85A (Tuberculosis vaccine)


University of Oxford, Centre for Clinical Vaccinology and Tropical Medicine
United Kingdom




University of Oxford

Results (where available)

View Results


Published on BioPortfolio: 2014-08-27T03:40:39-0400

Clinical Trials [2672 Associated Clinical Trials listed on BioPortfolio]

T−Cell Turnover Following Vaccination With MVA85A

This study examines the early immune response to a new vaccine (MVA85A) being developed to combat tuberculosis (TB).

MVA85A Aerosol vs Intramuscular Vaccination in Adults With Latent Mycobacterium Tuberculosis (M. tb) Infection

TB040 is a clinical trial to investigate and compare the effects of a candidate Tuberculosis (TB) vaccine, MVA85A, administered by the aerosol inhaled route and the intramuscular route in ...

A Study of MVA85A in Healthy Infants

This is a Phase II double-blinded randomized controlled evaluation of safety, immunogenicity and efficacy of MVA85A/AERAS-485 in BCG vaccinated infants without tuberculosis or HIV infectio...

Safety, Immunogenicity, and Impact of MVA85A, on the Immunogenicity of the EPI Vaccines

This study is preliminary to proving that this vaccine could protect against tuberculosis in humans. Although there is no proven data to show that infants will benefit directly from partic...

A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Previously Received BCG

This is a phase I study to examine the safety and immunogenicity of MVA85A delivered intradermally into the deltoid region in volunteers who have recieved BCG in the past 20 years.

PubMed Articles [2370 Associated PubMed Articles listed on BioPortfolio]

Prospects for a vaccine to prevent HIV-related tuberculosis.

To outline the need for a new tuberculosis (TB) vaccine; challenges for induction of vaccine-mediated protection in HIV-infected persons; and recent advances in clinical development.

Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination.

Recent Mycobacterium tuberculosis infection confers a predisposition to the development of tuberculosis disease, the leading killer among global infectious diseases. H4:IC31, a candidate subunit vacci...

Anatomic and Cellular Niches for Mycobacterium tuberculosis in Latent Tuberculosis Infection.

Latent tuberculosis has been recognized for over a century, but discovery of new niches, where Mycobacterium tuberculosis resides, continues. We evaluated literature on M.tuberculosis locations during...

Latent tuberculosis infection and tuberculosis in children and adolescents.

To describe the characteristics of patients diagnosed with tuberculosis and latent tuberculosis infection.

Novel M. tuberculosis specific IL-2 ELISpot assay discriminates adult patients with active or latent tuberculosis.

Tuberculosis (TB) still is a major worldwide health problem, with 10.4 million new cases in 2016. Only 5-15% of people infected with M. tuberculosis develop TB disease while others remain latently inf...

Medical and Biotech [MESH] Definitions

The dormant form of TUBERCULOSIS where the person shows no obvious symptoms and no sign of the causative agent (Mycobacterium tuberculosis) in the SPUTUM despite being positive for tuberculosis infection skin test.

Tuberculosis of the brain, spinal cord, or meninges (TUBERCULOSIS, MENINGEAL), most often caused by MYCOBACTERIUM TUBERCULOSIS and rarely by MYCOBACTERIUM BOVIS. The infection may be limited to the nervous system or coexist in other organs (e.g., TUBERCULOSIS, PULMONARY). The organism tends to seed the meninges causing a diffuse meningitis and leads to the formation of TUBERCULOMA, which may occur within the brain, spinal cord, or perimeningeal spaces. Tuberculous involvement of the vertebral column (TUBERCULOSIS, SPINAL) may result in nerve root or spinal cord compression. (From Adams et al., Principles of Neurology, 6th ed, pp717-20)

Pathological conditions of the CARDIOVASCULAR SYSTEM caused by infection of MYCOBACTERIUM TUBERCULOSIS. Tuberculosis involvement may include the HEART; the BLOOD VESSELS; or the PERICARDIUM.

TUBERCULOSIS that involves any region of the GASTROINTESTINAL TRACT, mostly in the distal ILEUM and the CECUM. In most cases, MYCOBACTERIUM TUBERCULOSIS is the pathogen. Clinical features include ABDOMINAL PAIN; FEVER; and palpable mass in the ileocecal area.

Tuberculosis of the mouth, tongue, and salivary glands.

More From BioPortfolio on "A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers."

Quick Search


Relevant Topics

A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe, its toxins or one ...

An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Tuberculosis TB
Tuberculosis (TB) is an infectious disease caused by bacteria belonging to the Mycobacterium tuberculosis complex. Over nine million new cases of TB, and nearly two million deaths from TB, are estimated to occur around the world every year, and new inf...

Searches Linking to this Trial